Access Pharma anticipates completion and delivery of its CobOral insulin formulation to the pharmaceutical company by the end of the month.
Access Pharma has recently signed an agreement with a biopharmaceutical company to develop an oral formulation of its marketed injectable for prostate cancer.
In addition, Access Pharma has filed supplementary patents covering the application of both platforms, CobOral (oral delivery) and CobaCyte (disease targeting), with most of the top 100 currently-marketed, injectable drugs.
Access Pharma’s CobOral product development program initially focused on the oral delivery of insulin and human growth hormone (hGH), two peptides which currently can only be given by injection.
Access Pharma president and CEO Jeffrey Davis said that they continue executing on their strategy for unlocking the value of the CobOral and CobaCyte platform technologies through formulation agreements with high-quality partner.
"The CobOral technology has potential in creating oral versions of currently marketed injectables, while providing our partners a valuable patent life-cycle management tool that can secure the IP extension on existing products," Davis said.